Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · Real-Time Price · USD

1.050

-0.030 (-2.78%)

Sep 5, 2025, 4:00 PM - Market closed

Estrella Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	3.85	3.14	3.2	0.66	0.3	0.28
Research & Development	8.24	5.72	4.11	10.45	1.39	0.46
Operating Expenses	12.08	8.85	7.31	11.11	1.69	0.73
Operating Income	-12.08	-8.85	-7.31	-11.11	-1.69	-0.73
Pretax Income	-12.08	-8.85	-7.31	-11.11	-1.69	-0.73
Income Tax Expense	-0	0	0	-	-	-
Net Income	-12.08	-8.85	-7.31	-11.11	-1.69	-0.73
Preferred Dividends & Other Adjustments	-	-	-	-	-0.61	-
Net Income to Common	-12.08	-8.85	-7.31	-11.11	-1.07	-0.73
Shares Outstanding (Basic)	37	37	27	0	-	-
Shares Outstanding (Diluted)	37	37	27	0	-	-
Shares Change (YoY)	34.72%	34.73%	8764.81%	-	-	-
EPS (Basic)	-0.33	-0.24	-0.27	-36.35	-	-
EPS (Diluted)	-0.33	-0.24	-0.27	-36.35	-	-
EBIT	-12.08	-8.85	-7.31	-11.11	-1.69	-0.73

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q